Sarepta’s Gene Therapy Impresses In Limb-Girdle Muscular Dystrophy
Pivotal Study Planned For 2021
Executive Summary
Positive functional results from Sarepta’s SRP-9003 gene therapy in limb-girdle muscular dystrophy type 2E bodes well for a pivotal study, and for the company’s studies of other potential gene therapies in Duchenne muscular dystrophy.
You may also be interested in...
Hansa Raises $121m To Fund Idefirix Launch
Having recently signed a gene therapy collaboration with Sarepta and received a positive opinion from the CHMP for its kidney transplant therapy, Sweden's Hansa has now raised a substantial sum in a "multiple times oversubscribed" placing.
Stockwatch: Age And Outcome Duration Cloud Innovative Therapy Reimbursement
Gene and cellular therapies that can replace decades of expensive therapy do not come cheap. Even the initial remedy of payment by installments could be irrelevant when not all patients respond in the same way.
Pfizer Planning To Start Phase III DMD Gene Therapy Trial, With Safety Monitoring Protocols
Updated Phase Ib data showed safety issues due to complement activation, but Pfizer is confident the benefits outweigh the risks and monitoring systems will help as it moves into Phase III.